nocodazole and jnj-7706621

nocodazole has been researched along with jnj-7706621 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hara, A; Kawai, G; Kimura, M; Matsuhashi, A; Nagano, A; Ohno, T; Okano, Y; Saio, M; Saitou, M; Shimizu, K; Takigami, I; Yamada, K	1
Baer, C; Breyssens, H; Brown, NR; Caballero, OL; Cebon, J; Endicott, J; Goding, CR; Hu, Y; John, T; Jones, EY; Kessler, BM; Knapp, S; Lu, M; Lu, X; Middleton, MR; Ratnayaka, I; Salter, V; Siebold, C; Sullivan, A; Sviderskaya, EV; Zhong, S	1

Other Studies

2 other study(ies) available for nocodazole and jnj-7706621

Article	Year
Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases. Current cancer drug targets, 2012, Volume: 12, Issue:6 Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Bone Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Cyclin-Dependent Kinases; Cytokinesis; Dose-Response Relationship, Drug; HeLa Cells; Humans; Mice; Mice, Nude; Mitosis; Neoplasms; Nocodazole; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Sarcoma, Ewing; Spindle Apparatus; Time Factors; Triazoles; Tubulin Modulators; Tumor Burden; Xenograft Model Antitumor Assays	2012
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer cell, 2013, May-13, Volume: 23, Issue:5 Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cyclin B1; Dimerization; Humans; Imidazoles; Indoles; Intracellular Signaling Peptides and Proteins; M Phase Cell Cycle Checkpoints; Melanoma; Mice; Neoplasm Metastasis; Nocodazole; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-mdm2; Repressor Proteins; Sulfonamides; Triazoles; Tumor Suppressor Protein p53; Vemurafenib; Xenograft Model Antitumor Assays	2013

Article

Year

Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.

Current cancer drug targets, 2012, Volume: 12, Issue:6

Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Bone Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Cyclin-Dependent Kinases; Cytokinesis; Dose-Response Relationship, Drug; HeLa Cells; Humans; Mice; Mice, Nude; Mitosis; Neoplasms; Nocodazole; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Sarcoma, Ewing; Spindle Apparatus; Time Factors; Triazoles; Tubulin Modulators; Tumor Burden; Xenograft Model Antitumor Assays

2012

Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP.

Cancer cell, 2013, May-13, Volume: 23, Issue:5

Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cyclin B1; Dimerization; Humans; Imidazoles; Indoles; Intracellular Signaling Peptides and Proteins; M Phase Cell Cycle Checkpoints; Melanoma; Mice; Neoplasm Metastasis; Nocodazole; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-mdm2; Repressor Proteins; Sulfonamides; Triazoles; Tumor Suppressor Protein p53; Vemurafenib; Xenograft Model Antitumor Assays

2013